Novel indole derivatives as potential anticancer agents: Design, synthesis and biological screening

To prepare the anticancer indoles, a series of substituted heteroannulated indole derivatives has been synthesized and characterized by spectral and elemental analysis. Subsequently they were evaluated for anticancer activity against cervical cancer (HeLa) cell line using MTT assay. Compounds 5c and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicinal chemistry research 2018, Vol.27 (1), p.321-331
Hauptverfasser: Prakash, B., Amuthavalli, A., Edison, D., Sivaramkumar, M. S., Velmurugan, R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To prepare the anticancer indoles, a series of substituted heteroannulated indole derivatives has been synthesized and characterized by spectral and elemental analysis. Subsequently they were evaluated for anticancer activity against cervical cancer (HeLa) cell line using MTT assay. Compounds 5c and 5d exhibit excellent activity with the IC 50 value of 13.41 and 14.67 µM, respectively which is nearer to the standard cisplatin (IC 50 -13.20 µM). All the compounds were further screened for their antibacterial activity against five gram negative and two gram positive bacterial strains to assess their selectivity. In order to get more insight into the binding mode and inhibitor binding affinity, compounds ( 4a – 5d ) were docked with Human protein kinase CK2. Results suggested that the hydrophobic interactions in the binding pockets of human protein kinase CK2 exploited affinity of the most favorable binding ligands ( 4c and 5c : glide score = −7.011 and −6.974: E-model score = −50.6 and −50.865, respectively). The structure–activity relationship (SAR) studies demonstrated that the most potent compounds ( 5c , 5d ) can be developed into precise the capability to treat cervical cancer.
ISSN:1054-2523
1554-8120
DOI:10.1007/s00044-017-2065-9